Skip to search formSkip to main contentSkip to account menu

zoledronic acid

Known as: 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid, zoledronic acid [Chemical/Ingredient] 
A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid… 
National Institutes of Health

Related topics

Related topics

24 relations
100 ML zoledronic acid 0.05 MG/ML Injection100 ML zoledronic acid 0.05 MG/ML Injection [Reclast]5 ML zoledronic acid 0.8 MG/ML Injection5 ML zoledronic acid 0.8 MG/ML Injection [Zometa]

Broader (3)

Bone Density Conservation AgentsDiphosphonatesImidazoles

Narrower (6)

CGP 42446AReclastZOL 446Zometa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study
The Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study assessed the progressive… 
Highly Cited
2015
Highly Cited
2015
Selective efficacy of zoledronic acid on metastasis in a patient‐derived orthotopic xenograph (PDOX) nude‐mouse model of human pancreatic cancer
Patient‐derived orthotopic xenograft (PDOX) nude‐mouse models replicate the behavior of clinical cancer, including metastasis… 
2012
2012
Zoledronic Acid
SummaryAbstractZoledronic acid (Zometa®), a third-generation amino-bisphosphonate, has been approved in the US, the EU and many… 
2011
2011
The use of zoledronic acid in pediatric cancer patients
The third generation bisphosphonate zoledronic acid has demonstrated efficacy in reducing skeletal‐related events in adult… 
Highly Cited
2010
Highly Cited
2010
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Bone disease is a major complication of multiple myeloma (MM) [1]. Bortezomib is the first-in-class proteasome inhibitor, with… 
2008
2008
Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC)
9588 Background: ONJ is diagnosed with increasing frequency among IV bisphosponate (IVBP)-treated cancer pts, in the range of 1… 
Highly Cited
2005
Highly Cited
2005
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid
Once bone metastasized and androgen independent, prostate cancer is often associated with skeletal morbidity and disability. New… 
2005
2005
Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
Zoledronic acid (ZOL), the most potent known bisphosphonate, is clinically efficacious against advanced prostate cancer, although… 
2003
2003
Zoledronic Acid Inhibits Osteoclastogenesis in Vitro and in a Mouse Model of Inflammatory Osteolysis
This study assessed effects of the bisphosphonate zoledronic acid (ZLNA) on osteoclastogenesis. To assess the effect of ZLNA on… 
Review
2003
Review
2003
Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving i.v. therapies. The use… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)